Type of publication:
Service improvement case study
Author(s):
*Dr. Sairah Anjum (FY2)
Citation:
SaTH Improvement Hub, May 2023
Abstract:
Guidance was recently approved and uploaded to the SaTH intranet (early April 2023), stating that high risk NOF fracture patients or those unable to tolerate oral bisphosphonates are more likely to benefit from a single 4mg infusion of zoledronic acid followed by 2 weeks of calcium & Vitamin D supplementation, with an overall aim of increasing bone density and reducing risk of further fragility fractures by ~50% by 10th May 2023.
Link to PDF poster [no password required]
